Literature DB >> 10741728

Antitumor activity of N-(2-hydroxypropyl) methacrylamide copolymer-Mesochlorine e6 and adriamycin conjugates in combination treatments.

J G Shiah1, Y Sun, C M Peterson, R C Straight, J Kopecek.   

Abstract

This study demonstrates the selective tumor targeting and the antitumor efficacy of the N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound mesochlorin e6 monoethylenediamine (Mce6) and HPMA copolymer-bound Adriamycin (ADR) in combination photodynamic therapy (PDT) and chemotherapy against human ovarian OVCAR-3 carcinoma xenografted in female athynmic mice. The concentrations of Mce6 and ADR in blood and tissues, in free or HPMA copolymer-bound form, were determined by fluorescence and high-performance liquid chromatography fluorescence assays, respectively. Xenograft responses to single and combination therapies were recorded. The peak concentration of HPMA copolymer-Mce6 conjugate in tumor was achieved 18 h after administration. For HPMA copolymer-bound drugs, the concentration ratios of liver and spleen versus muscle were significantly higher than those of free drugs. The HPMA copolymer-bound drugs demonstrated selective targeting and accumulation in the tumor, probably attributed to the enhanced permeability and retention effect. In vivo studies revealed that all tumors in the treatment groups showed significant responses after receiving any of the various types of therapy as compared with controls (P < 0.001). PDT with HPMA copolymer-Mce6 conjugate (PDTMC) at a dose of 13.4 mg/kg (1.5 mg/kg of Mce6 equivalent) and light doses of 110 J/cm2 at 12 and 18 h, respectively, resulted in significant suppression of the growth of OVCAR-3 tumors. Three courses of chemotherapy using 35 mg/kg (2.2 mg/kg of ADR equivalent) of HPMA copolymer-ADR conjugate (CHEMO) were effective in suppressing the growth of tumors. Single PDTMC plus multiple CHEMO exhibited significantly greater therapeutic efficacy than multiple CHEMO. In the group of mice receiving multiple PDTMC, tumor recurrence became obvious after day 20. However, 10 of 12 tumors exhibited complete responses in the group of mice receiving multiple PDTMC plus multiple CHEMO. The least to most effective treatments were ranked as follows: multiple CHEMO < single PDTMC plus multiple CHEMO < multiple PDTMC < multiple PDTMC plus multiple CHEMO. The results clearly demonstrate that: (a) HPMA copolymer-bound drugs exhibited selective tumor accumulation contrary to free drugs; (b) PDT using HPMA copolymer-Mce6 conjugate with multiple light irradiations was a better therapy than that with single light irradiation; and (c) combination chemotherapy and photodynamic therapy with HPMA copolymer-ADR and HPMA copolymer-Mce6 conjugates was the most effective regimen.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10741728

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  18 in total

1.  Biopolymer-based delivery systems for advanced imaging and skeletal tissue-specific therapeutics.

Authors:  Scott C Miller; Dong Wang; Pavla Kopecková; Jindrich Kopecek
Journal:  J Bone Miner Metab       Date:  2005       Impact factor: 2.626

2.  Syntheses and cellular investigations of 17(3)-, 15(2)-, and 13(1)-amino acid derivatives of chlorin e(6).

Authors:  R G Waruna Jinadasa; Xiaoke Hu; M Graça H Vicente; Kevin M Smith
Journal:  J Med Chem       Date:  2011-10-07       Impact factor: 7.446

3.  Biomaterials and drug delivery: past, present, and future.

Authors:  Jindrich Kopecek
Journal:  Mol Pharm       Date:  2010-08-02       Impact factor: 4.939

4.  Photoimmunotherapy and irradiance modulation reduce chemotherapy cycles and toxicity in a murine model for ovarian carcinomatosis: perspective and results.

Authors:  Imran Rizvi; Tri A Dinh; Weiping Yu; Yuchiao Chang; Margaret E Sherwood; Tayyaba Hasan
Journal:  Isr J Chem       Date:  2012-09       Impact factor: 3.333

5.  Combination cytotoxicity of backbone degradable HPMA copolymer gemcitabine and platinum conjugates toward human ovarian carcinoma cells.

Authors:  Acharaporn Duangjai; Kui Luo; Yan Zhou; Jiyuan Yang; Jindřich Kopeček
Journal:  Eur J Pharm Biopharm       Date:  2013-12-04       Impact factor: 5.571

6.  POLYMERIC BIOMATERIALS AND NANOMEDICINES.

Authors:  Jiyuan Yang; Jindřich Kopeček
Journal:  J Drug Deliv Sci Technol       Date:  2015-12-01       Impact factor: 3.981

7.  Contrast-enhanced MRI-guided photodynamic cancer therapy with a pegylated bifunctional polymer conjugate.

Authors:  Anagha Vaidya; Yongen Sun; Yi Feng; Lyska Emerson; Eun-Kee Jeong; Zheng-Rong Lu
Journal:  Pharm Res       Date:  2008-06-27       Impact factor: 4.200

Review 8.  Biological rationale for the design of polymeric anti-cancer nanomedicines.

Authors:  Yan Zhou; Jindřich Kopeček
Journal:  J Drug Target       Date:  2012-09-26       Impact factor: 5.121

9.  Enhanced antitumor activity of combinations of free and HPMA copolymer-bound drugs.

Authors:  J Hongrapipat; P Kopecková; S Prakongpan; J Kopecek
Journal:  Int J Pharm       Date:  2007-09-22       Impact factor: 5.875

Review 10.  Macromolecular therapeutics.

Authors:  Jiyuan Yang; Jindřich Kopeček
Journal:  J Control Release       Date:  2014-04-18       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.